ProKidney Corp’s filing revealed that its SVP of Regulatory Development Weber Darin J. unloaded Company’s shares for reported $41315.0 on Apr 22 ’24. In the deal valued at $2.51 per share,16,438 shares were sold. As a result of this transaction, Weber Darin J. now holds 155,194 shares worth roughly $0.34 million.
Then, Weber Darin J. sold 800 shares, generating $2,028 in total proceeds. Upon selling the shares at $2.54, the SVP of Regulatory Development now owns 171,632 shares.
Before that, Weber Darin J. sold 17,238 shares. ProKidney Corp shares valued at $43,095 were divested by the SVP of Regulatory Development at a price of $2.50 per share. As a result of the transaction, Weber Darin J. now holds 172,432 shares, worth roughly $0.38 million.
A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. BTIG Research began covering PROK with “Buy” recommendation on July 25, 2023. Jefferies started covering the stock on December 21, 2022. It rated PROK as “a Buy”.
Price Performance Review of PROK
On Friday, ProKidney Corp [NASDAQ:PROK] saw its stock jump 2.33% to $2.20. Over the last five days, the stock has gained 3.77%. ProKidney Corp shares have risen nearly 23.60% since the year began. Nevertheless, the stocks have fallen -76.50% over the past one year. While a 52-week high of $13.51 was reached on 04/17/24, a 52-week low of $1.12 was recorded on 02/13/24. SMA at 50 days reached $1.79, while 200 days put it at $3.71. A total of 0.57 million shares were traded, compared to the trading of 0.35 million shares in the previous session.
Levels Of Support And Resistance For PROK Stock
The 24-hour chart illustrates a support level at 2.03, which if violated will result in even more drops to 1.86. On the upside, there is a resistance level at 2.37. A further resistance level may holdings at 2.54. The Relative Strength Index (RSI) on the 14-day chart is 52.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.23, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.39%. Stochastics %K at 25.54% indicates the stock is a holding.
The most recent change occurred on November 10, 2022 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $13 price target.
